- Participating in the PharmaLab Expo Tokyo during Nov 25-27 to jumpstart outreach Sai Life Sciences, one of India's fastest growing Contract Research, Development & Manufacturing Organizations [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=opens-repres entative-office-in-japan] (CRO-CDMO), announced the opening of its representative office in Tokyo, Japan. The new office will serve as base for the company's outreach to innovator pharmaceutical and biotech companies in Japan and other countries in the Asia Pacific region. A seasoned industry specialist, Mr. Junjiro Sato has been appointed as Representative Director to be based in Tokyo and spearhead the efforts. Sai Life Sciences will be participating in the PharmaLab Expo Tokyo (held inside INTERPHEX Week) during Nov 25-27, 2020 to create awareness about its unique service offerings across drug discovery, development and commercialization. Sai Life Sciences already has a significant connection with the Japanese market. It was the launch site for commercial API supplies of an NCE to Japan and has supplied over 10 tonnes of API with batch sizes of 50 Kg to 150 Kg scale over the past 4 years. It also is a supplier of registered starting materials for two other commercial APIs. From a Discovery perspective, the company has helped several biotech and pharma companies advance programs from HIT to lead optimization/ candidate stage, through its chemistry, biology and DMPK services. Over the past two decades, Sai Life Sciences has served a diverse set of NCE development programmes, consistently delivering value based on its quality and responsiveness. It has a 100% successful track record of regulatory inspections across its R&D and manufacturing facilities from both FDA and PMDA. Today, it works with 7 of the top 10 large pharma companies, in addition to several small and mid-sized pharma & biotech companies. It has over 2000 employees across its facilities in India, UK and USA. Coinciding with its 20th anniversary in 2019, the company announced Sai Nxt, an organisation-wide initiative aimed at transforming itself into a new generation CRO-CDMO. Guided by insights and feedback from customers, it is investing over US$150M to significantly expand and upgrade its R&D and manufacturing facilities, deepen scientific capabilities, strengthen automation and data systems, and above all raise the bar for safety, quality and customer focus. About Sai Life Sciences Sai Life Sciences is a full-service CRO/ CDMO [https://www.sailife.com/?utm_source=pr&utm_medium=web&utm_campaign=opens-repres entative-office-in-japan] driven by a vision to support the launch of 25 new medicines by 2025. It works with innovator pharma and biotech companies globally, accelerating the discovery, development and manufacture of complex small molecules. A pure-play CDMO, Sai Life Sciences has served a diverse set of NCE development programs, consistently delivering value based on its quality and responsiveness. Today, it works with 7 of the top 10 large pharma companies, as well as several small and mid-sized pharma & biotech companies. Sai Life Sciences is privately held and backed by global investors, TPG Capital and HBM Healthcare Investments. https://www.sailife.com Photo: https://mma.prnewswire.com/media/1336500/Junjiro_Sato_Sai_Life_Sciences.jpg Logo: https://mma.prnewswire.com/media/1044186/Sai_Life_Sciences_Logo.jpg Source: Sai Life Sciences